How should I choose between Sotorasib and Adagrasib?

Sotorasib and adagrasib (Adagrasib) are two new anti-cancer drugs targeting KRAS G12C mutations, specifically used to treat KRAS G12Cmutant non-small cell lung cancer (NSCLC). Although they share similarities in their mechanisms of action and therapeutic targets, they differ in some respects, so a patient's choice of which drug to use may depend on a range of factors.

1. Drug action mechanism:

Sotorasiib: By inhibiting the activity ofKRAS G12C mutant, it blocks abnormal signaling pathways in cancer cells, thereby inhibiting the growth and spread of tumors.

Adagrasib: It is also a KRAS G12C inhibitor that inhibits KRAS G12C mutants through a similar mechanism and blocks the growth of tumors.

2. Clinical trial results:

Sotoracib: In clinical trials, it has shown certain efficacy and significant anti-tumor activity in patients with KRAS G12C mutated non-small cell lung cancer.

Adagrasiib: has also shown encouraging results in clinical trials, with some patients showing tumor shrinkage or stabilization after treatment.

3. Drug characteristics and side effects:

Sotorasiib: May cause some side effects, such as fatigue, nausea, diarrhea, etc. Patients need to be monitored regularly and evaluated by a doctor.

Adagrasiib: It may also be associated with side effects, including but not limited to nausea, diarrhea, respiratory problems, etc. Close monitoring and communication with the doctor are required.

4. Individual differences and customized treatment plans:

Due to individual patient differences, responses to medications may vary. Some patients may be more sensitive to one drug than another, requiring individualized treatment based on their individual condition.

5. Drug resistance and treatment options:

Drugs targeting the KRAS G12C mutation may face resistance issues, so patients who fail first-line therapy may need to switch to another drug.

6. Research and future prospects:

The efficacy and safety of these two drugs are still being evaluated in further studies, and more data and understanding may be generated in the future to provide more guidance on treatment options for patients.

When choosing sotoracib or adagrasiib, patients should make a comprehensive consideration based on their doctor's advice, combined with their individual conditions, clinical trial data and drug characteristics. Currently, both drugs are intended to provide new treatment options for KRAS G12C mutated non-small cell lung cancer, and patient choice may be affected by many factors such as individual differences, clinical conditions, and doctor's recommendations. With the deepening of research and the development of medical practice, we can expect to gain a more comprehensive understanding of these two drugs and provide patients with more personalized and effective treatment options. Patients need to work closely with their doctors during medication and report any discomfort in a timely manner to ensure the best effect of treatment.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.